How OEMs can budget aftermarket service in a recession
OEMs need to rethink how to deliver scalable, flexible service, especially in economic uncertainty.
How OEMs can budget aftermarket service in a recession Read More »
Uncategorized
XNK receives certificate of GMP compliance of a manufacturer from the Medical Products Agency
XNK Therapeutics announced that it has received a GMP manufacturing license and a certificate of GMP compliance from the Swedish Medical Products Agency, which means that the company can produce at scale for its planned clinical studies.
New data by AKL Therapeutics suggests investigational oral osteoarthritis drug APPA may have a promising senotherapeutic effect with potential in other diseases of ageing
New data* presented at the 2023 Osteoarthritis Research Society International World Congress in Denver, Colorado suggest that AKL Therapeutics’ investigational oral osteoarthritis drug APPA** may have a dual effect on senescence.
Antengene Announces Five Upcoming Presentations at the 2023 American Association for Cancer Research Annual Meeting
Antengene Corporation Limited announced the publication of abstracts for five posters that will be presented during the upcoming 2023 American Association for Cancer Research Annual Meeting, taking place from April 14th to 19th at the Orange County Convention Center in Orlando, Florida, the United States.
Oxford Nanopore and 4bases Announce Collaboration to Combine Nanopore Sequencing Devices and 4bases Kits to Support Rapid, High-accuracy Analyses in Human and Cancer Genetics, with a First Target of Same-day BRCA1 and BRCA2 Analysis
Oxford Nanopore Technologies plc and 4bases, a Switzerland-based company, specialising in kits for sequencing and bioinformatic tools, announce a collaboration to make available 4bases kits with Oxford Nanopore sequencing technology.
VILTEPSO® (viltolarsen) injection Open Label Extension Clinical Trial Data Scheduled for Presentation at the MDA Clinical & Scientific Conference 2023
NS Pharma is pleased to announce participation in the Muscular Dystrophy Association’s Clinical & Scientific Congress 2023 being held in Dallas, Texas. The company will be presenting previously reported long-term efficacy and safety data from the open-label extension of a Phase 2 study of VILTEPSO®.
Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset
Novartis presented new data which underscore the transformational and sustained benefit of Zolgensma®, an essential one-time gene therapy for the treatment of spinal muscular atrophy.
Patritumab Deruxtecan Continues to Show Encouraging Clinical Activity in Distinct Patient Populations with Metastatic Lung and Breast Cancer in Updated Results of Two Early Trials
New data from Daiichi Sankyo’s patritumab deruxtecan from two early trials in patients with previously treated EGFR-mutated metastatic non-small cell lung cancer or HER3 expressing metastatic breast cancer were presented during two Presidential Sessions at the Japanese Society of Medical Oncology Annual Meeting.
Kangpu Completes Patient Enrollment for Phase IIa Clinical Trial of KPG-818 in SLE in the US
Kangpu Biopharmaceuticals, a clinical-stage company based in Shanghai, China, announced that the Company has completed patient enrollment for the Phase IIa clinical trial of KPG-818 aimed at the treatment of systemic lupus erythematosus in the US.
Eisai Publishes Societal Value of Lecanemab Using Phase 3 Clarity Ad Data in Peer-reviewed Neurology and Therapy Journal
Eisai Co., Ltd. announced the publication of updated results from an evaluation estimating the societal value of anti-amyloid-beta protofibril* antibody lecanemab in people living with mild cognitive impairment due to Alzheimer’s disease and mild AD using data from the Phase 3 clinical study, Clarity AD by applying a validated disease simulation model.